Recent News

• 10.06.2025 - Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
• 10.06.2025 - Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
• 09.29.2025 - Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
• 09.29.2025 - Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
• 09.18.2025 - Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
• 09.18.2025 - Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
• 09.15.2025 - Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
• 09.15.2025 - Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
• 08.11.2025 - Humacyte Second Quarter 2025 Financial Results and Corporate Update
• 08.11.2025 - Humacyte Second Quarter 2025 Financial Results and Corporate Update

Recent Filings

• 09.22.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 09.22.2025 - EFFECT Notice of Effectiveness
• 09.18.2025 - 8-K Current report
• 09.12.2025 - S-3 Registration statement under Securities Act of 1933
• 08.20.2025 - 144 Report of proposed sale of securities
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 144 Report of proposed sale of securities
• 08.18.2025 - 144 Report of proposed sale of securities